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Abstract
Background: HIV is the leading cause of death among adults in sub-Saharan Africa. However, mortality along the
HIV care continuum is poorly described. We combine demographic, epidemiologic, and health services data to
estimate where are people with HIV dying along Rwanda’s care continuum.
Methods: We calibrated an age-structured HIV disease and transmission stochastic simulation model to the epidemic
in Rwanda. We estimate mortality among HIV-infected individuals in the following states: untested, tested without
establishing care in an antiretroviral therapy (ART) program (unlinked), in care before initiating ART (pre-ART), lost to
follow-up (LTFU) following ART initiation, and retained in active ART care. We estimated mortality among people living
with HIV in Rwanda through 2025 under current conditions, and with improvements to the HIV care continuum.
Results: In 2014, the greatest portion of deaths occurred among those untested (35.4%), followed by those on ART
(34.1%), reflecting the large increase in the population on ART. Deaths among those LTFU made up 11.8% of all deaths
among HIV-infected individuals in 2014, and in the base case this portion increased to 18.8% in 2025, while the
contribution to mortality declined among those untested, unlinked, and in pre-ART. In our model only combined
improvements to multiple aspects of the HIV care continuum were projected to reduce the total number of deaths
among those with HIV, estimated at 8177 in 2014, rising to 10,659 in the base case, and declining to 5,691 with
combined improvements in 2025.
Conclusion: Mortality among those untested for HIV contributes a declining portion of deaths among HIV-infected
individuals in Rwanda, but the portion of deaths among those LTFU is expected to increase the most over the next
decade. Combined improvements to the HIV care continuum might be needed to reduce the number of deaths
among those with HIV.
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Background
The number of HIV infected individuals receiving anti-
retroviral therapy (ART) in Sub-Saharan Africa is steadily
increasing [1]. The expansion of ART provision has led to
important declines in HIV-related and all-cause adult mor-
tality [2–4]. However, the declining global estimates of HIV
mortality belie the fact that, in 2013, HIV was responsible
for more deaths than any other single cause in sub-Saharan
Africa [5, 6]. A major challenge for addressing mortality
among those with HIV is the incomplete understanding of
what patient groups are at the highest risk of mortality.
This understanding can inform the prioritization of pro-
grams targeting at-risk populations. We aimed to use data
from the Rwandan HIV population to estimate mortality
along the continuum of care.
The HIV care continuum, sometimes referred to as the
care cascade, is a paradigm for understanding the states in
the health care system that HIV-infected individuals find
themselves following HIV infection [7]. Estimates of the
continuum in the United States, for example, suggest that
only 30% of all HIV-positive patients were virally sup-
pressed in 2011, with notable gaps prior to HIV testing,
after testing and before ART initiation, and after ART
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initiation [8]. However, healthcare systems are poorly
equipped to monitor the vital status of patients outside
ART programs, and may fail to distinguish between patient
loss from care, transition to other healthcare facilities, and
death [9]. As Rwanda’s public health system ensures that
most patient transfers and mortality are identified, a unique
opportunity exists to assess patient tracking through the
HIV care continuum [10]. We used nationally representa-
tive data from Rwanda and modeled this using a transmis-
sion simulation model.
Methods
Setting
Rwanda’s HIV/AIDS strategy has been a positive outlier in
its ability to engage large segments of the population, in-
cluding typically hard to service populations, such as men
and adolescents [11]. Since 2002, a National Strategic Plan
set aggressive targets for increasing ART coverage using a
decentralized network of clinics principally staffed by com-
munity health workers [12]. Rwanda has outpaced many
other countries in increasing ART coverage (defined as the
portion of all infected individuals that are receiving ART)
[1]. In addition, nearly all care in Rwanda is provided by the
public sector (less than 1% of patients attend private clinics
according to national surveillance data) [13].
Model description
We calibrated a dynamic stochastic microsimulation model
of HIV disease and transmission to Rwanda’s HIV epidemic
to study where in the HIV care continuum are people dying
[14–17]. The model uses information on the transition of
patients through the health care system from a national
source of HIV care in the public sector [10]. We used the
model to estimate the distribution and trends of mortality.
Specifically, we examined where along the HIV care con-
tinuum are HIV-infected individuals dying, and how this
trend is expected to change in the next decade. We also ex-
amined how HIV treatment and prevention programs ad-
dressing different aspects of HIV care delivery would be
expected to affect future mortality patterns.
The model simulates HIV transmission, testing, treat-
ment, and disease progression in individuals, using an age-
and gender-stratified demographic model fit to Rwanda’s
population [18]. We modeled a population ages 15 and
older, and assumed a stable population growth rate of 2.6%
per year [18, 19]. The model is calibrated to several epide-
miologic trends from 2003 to 2014, including population
size, HIV testing coverage, ART coverage, and HIV preva-
lence [1, 10, 20, 21]. Complete model parameters, descrip-
tion, and calibration figures are shown in Additional file 1:
Sections S1 and S2.
We modeled disease transmission through heterosexual
contact. The infection status of HIV-negative individuals is
determined by their risk factors for acquiring HIV,
including the number of sexual partners, the HIV status of
their sexual partners, the infectivity of HIV-positive part-
ners, and, for men, their circumcision status. Partner distri-
bution and infectivity based on viral load is shown in the
parameter table. The initial distribution of sexual partners
was estimated from Rwanda’s 2005 Demographic and
Health Survey and updated through discussion with Minis-
try of Health participation [21]. The probability of having
an HIV-infected sexual partner is dynamically determined
in relation to the HIV prevalence in the opposite gender.
We assume homogenous mixing across ages, and did not
explicitly model special populations such as female sex
workers except through the distribution of sexual partner-
ships. For each individual with an HIV-positive partner, the
partner’s infectivity is determined by the distribution of
acutely infected, unsuppressed, and suppressed individuals
in the currently infected population. We assume that indi-
viduals with suppressed viral load on ART have 90% lower
risk of transmitting HIV per coital act compared with
chronic unsuppressed infection (the reduction in infectivity
is higher in comparison with acute HIV) [22, 23]. The
probability of infection for an uninfected individual, then, is
a product of their partners’ infection status and the trans-
mission hazard per person-month of contact given the part-
ner’s infectivity. The risk of acquiring HIV is 50% lower for
circumcised men [24, 25]. Additional demographic and
transmission parameters are provided in Table 1 and
Additional file 1: Section S1.
HIV disease, care, and mortality
Our model represents HIV disease and care along the care
continuum. Untreated HIV disease is represented as a
chronic progressive disease in which a declining CD4
count defines the risk of mortality and development of op-
portunistic diseases (OD). Effective treatment with ART
leads to CD4 count increases that are based on age, CD4
count at treatment initiation, and duration of treatment.
Additional details on the disease progression assumptions
are in the Additional file 1 and previous articles [15, 16].
The flow of infected individuals through the HIV care
system is characterized by the following stages. Individuals
are unaware of their infection status prior to HIV testing
(we call this stage Untested); we calibrated the annual rate
of testing such that 33% of the adult population had been
tested by 2005 and 71% by 2013. In 2013, 80% of those who
tested positive were linked to care. We term those who are
aware of their status and never linked to care Unlinked.
During the period between initial linkage and ART initi-
ation, patients are said to be pre-ART, and may become
Leaked from care with a monthly probability of 0.5%. A
corollary is that late treatment initiation could lead to in-
creases in the number of leaked patients, who may re-
present to HIV care only when they develop an OD [10].
Rwanda uses CD4 cell counts staging for treatment
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initiation, and in our analysis patients initiate ART when
their measured CD4 count drops below 250 cells/mm3
(2003 to 2008), 350 cells/mm3 (2009–2013), or 500 cells/
mm3 (starting in 2014). Patients also qualify for ART when
they experience an OD. Given estimates of rates of trans-
mitted drug resistance, we estimate that 90% of those who
are adherent achieve viral suppression within 6 months of
ART initiation [26, 27]. Following ART initiation, patients
may be lost to follow-up (LTFU) with a monthly probability
of 0.0875% [10]. We use estimates that 50% of those LTFU
may return to care if they develop an OD [9, 10].
We used monthly mortality rates for each person as a
combined function of age, gender, and, for HIV-positive
individuals, CD4 count, and ART status. Age- and
gender-specific mortality for HIV-negative individuals
come from life tables for Rwanda and converted to
monthly probability of death [28]. We cause-delete the
contribution of HIV to overall mortality using estimates
of the portion of deaths due to HIV by age and gender
[29]. Thus, for HIV-negative individuals we apply cause-
deleted age- and gender-specific mortality. For HIV-
positive individuals, we model mortality as a function of
current CD4 cell count, with an additional short-term
risk of death during an acute OD event [30]. All the in-
fluential base case parameter and uncertainty values are
summarized in Table 1.
Table 1 Selected model parameters and base case assumptions
Parameter Base case value Uncertainty Source(s)
Demographic parameters
Life expectancy, 2003
Male 50.9 World Population Prospects [20]
Female 52.9 World Population Prospects [20]
Male circumcision prevalence 30% [20–40] Binagwaho et al. [33]
Number of sexual partnerships in 12-month period 2010 Rwanda DHS [21]
0 56% +/− 19%
1 36% +/− 9%
2 7% +/− 2%
3+ 1% +/− 0.25%
HIV program parameters
HIV testing: annual probability of receiving HIV test
2003–2010 20% 10–30% Rwanda DHS [21]
2010–2014 40% 35–45% Nsanzimana [10]
Portion of those tested who are connected to care
2003–2010 70% Nsanzimana [10]
2010–2014 90% Nsanzimana [10]
Rate of loss from pre-ART care 0.5% monthly 0.3–0.7% Nsanzimana [10]
ART initiation threshold (CD4 counts, cells/mm
3)
2003–2008 250 Nsanzimana [10] and NSP [34]
2008–2014 350
2014 500
Rate of loss to follow-up from ART care 0.0875% monthly 0.05–0.125% Nsanzimana [10]
Probability of return after loss from ART care 25% 20–30% Nsanzimana [10]
Morbidity & mortality parameters
Age-specific mortality Yearly Age-specific nqx WHO life tables [28]
CD4-specific mortality 6 CD4 bins Mortality rate by CD4 95% CI for each rate Nsanzimana [30], table 2
OD-specific risk by CD4 6 CD4 bins Mortality rate by CD4 95% CI for each rate Holmes [35]
Portion of the population ever tested for HIV, 2010
2005 30% Rwanda DHS
2010 65% Rwanda DHS
2013 78% Nsanzimana [10]
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Outcomes and sensitivity analyses
Our principal analyses address the following two ques-
tions: (1) where are HIV-infected individuals dying in the
context of Rwanda’s care continuum? and (2) how are
these patterns expected to vary with changes to HIV care
in Rwanda? In analyzing mortality, we measure deaths
among HIV-infected individuals in each of the following
groups: prior to HIV testing (Untested), among those with
a known HIV diagnosis but who are no linked to care
(Unlinked), after linkage to care but prior to ART initi-
ation (pre-ART, included leaked patients), among those in
ART care, and among those lost to follow-up (LTFU) after
ART initiation. We estimate mortality with two metrics:
the portion of all deaths taking place among individuals in
each group, and a mortality rate calculated as the number
of deaths divided by the number of person-years in the
group (age-adjusted using weighted average of rates in
each 5-year age group). The point estimates for the base
case were obtained after 100 model iterations. Uncertainty
in the results reflect both first-order (stochastic) variation
as well as second-order variation from a probabilistic sen-
sitivity analysis where parameters were jointly sampled
from the distributions spanning their uncertainty ranges
and the outcomes of interest were summarized after 1000
model iterations. Uncertainty bounds are reported as the
25–75% range among all model iterations.
In addition to the base-case estimations, we simulate
the expected changes in mortality under several potential
changes to Rwanda’s national strategic plan for HIV con-
trol. These include modeling the mortality changes follow-
ing intensifying annual testing rates from 40% to 90% of
the population; increasing linkage to care from 80% of the
tested population to 90% (for example using patient tra-
cing); reducing leakage from pre-ART 0.5% to 0.1% of the
pre-ART population per month; and improving rates of
LTFU from 0.0875% of those on ART to 0.05% per month.
We also simulated immediate ART initiation for all linked
HIV-positive individuals and one combined scenario
where all improvements were implemented. These im-
provements were constructed to reflect proposed inter-
ventions in Rwanda through early identification and offer
of ART to HIV-infected individuals, targeting of popula-
tions at high risk for infection, community support for re-
tention in ART programs, and peer networks to improve
maintenance in care and reduce rates of loss to follow-up.
All simulations were carried out in Matlab 2014b, and
analyses and visualizations in Stata 13.1.
Results
Our model is calibrated to Rwanda’s overall and age-
specific HIV prevalence from 2003 to 2013, and projected
forward to 2025. Between 2003 and 2005, we calibrated the
model to UNAIDS prevalence estimates among adults, de-
clining from 3.6% in 2003 to 3.3% in 2005 [1]. From 2005
to 2013, we used the Rwanda Demographic and Health
Surveys of 2005 and 2010, and the Rwanda AIDS Indicators
Survey of 2013 to obtain nationally representative adult
HIV prevalence estimates [21]. Adult HIV prevalence was
3.0% in all three surveys. Prevalence in our model declined
to 3.0% in 2007, and remained stable during the period
from 2007 to 2013. We calibrated overall prevalence as well
as age-specific prevalence in each 5-year age group, avail-
able from the Rwanda Demographic and Health Surveys.
Figure 1 shows the model’s calibration fitting overall preva-
lence estimates from 2003 to 2013 (panel A) as well as age-
specific prevalence rates seven years into the model is
started, in 2010 (panel B). Although we did not explicitly
calibrate incidence, our model’s incidence for 2013–2014
was 0.23 infections per 100 person-years, similar to the
0.27 estimate in the 2013–14 Rwanda HIV Incidence
Household Survey [31]. The Additional file 1 contains add-
itional calibration results.
Several demographic trends shape the mortality patterns.
First, a stable 3% adult HIV prevalence, combined with an
overall annual population growth rate of 2.6% implies a
steady growth in the HIV-positive population, estimated at
239,668 in 2014 and increasing 25.9% to 301,808 by the
end of 2025. Over the same time period, a continuation of
current HIV mortality rates imply an increase of 17.4% in
the number of deaths among those HIV-positive, from
12,971 in 2014 to 15,229 in 2025. While these estimates
represent substantial increases in HIV-infected populations
and deaths, they are smaller than the projected 32.6% in-
crease in the overall population size, suggesting a decline
from the present in HIV burden. Our baseline estimates of
the number of deaths are higher than UNAIDS estimates
of AIDS deaths since the model accounts for all deaths
among those with HIV, including non-AIDS deaths among
those with HIV. This increase in the number of deaths
among those with HIV reflects the balance between the up-
wards pressure on mortality from population growth and
aging of the HIV-infected population versus the declining
mortality from continued expansion of the population
accessing ART. As Rwanda’s HIV-infected population ages,
the portion of deaths made up by older individuals is also
expected to increase. Our model estimates that, in 2014,
10% of deaths among HIV-infected individuals took place
among those older than 65-years-old, and that this propor-
tion would increase to 24% in 2025. These changes in HIV
population patterns, including population growth and
aging, help frame the changing drivers of mortality.
Where are people dying along the care continuum?
Our base case mortality analysis suggests that in 2003,
untested individuals accounted for around five-sixths of
deaths among people with HIV (85.4% [80.1–90.5%] of
an estimated 17,025 deaths), but that this proportion
had declined with increasing testing coverage and the
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changing composition of those untested to include a
growing portion of asymptomatic individuals with rela-
tively higher CD4 counts. Figure 2 shows the time trends
and changes in mortality distribution under the base
case scenario. This results from selective testing of those
with ODs such that the testing rate is generally higher
among those with advanced disease, and from the op-
portunity to miss those with recent infections even when
testing rates are high, leading to a shift in the untested
population towards those with less advanced HIV (we
estimate that among those untested, the portion with
CD4 cell counts higher than 500 was 29.4% in 2003 and
59.3%in 2014). By 2014, the portion of deaths among
those untested declined to 35.4% (31.2-39.5% out of an
estimated 8,177 deaths among people with HIV). At the
same time, those on ART experienced the largest growth
in the proportion of deaths, from 2.7% in 2003 (1.1–
4.4%) to 34.1% in 2014 (29.9–38.4%). This is a reflection
of the large growth of people on ART, and accounts for
the overall decline in mortality rates among those with
HIV, since the mortality rate among those on ART is
lower than any other group. We project that, over the
next decade, the portion of all deaths made up by those
untested, unlinked, and pre-ART will decline, and the
portion of all deaths made up by those on ART and
LTFU will increase (where deaths on ART is a desirable
outcome of effective scale-up, while deaths among those
lost from care are undesirable). The greatest increase in
mortality is estimated to take place among those LTFU,
from 11.8% (11.1–12.5%) in 2014 to 18.8% (17.9–19.9%)
in 2025. While empirical observations and our modeled
population suggest that in 2013 those LTFU made up
3% of the population living with HIV, model findings
suggests that this group’s share of overall deaths is about
4 times higher than its share of the population, reflecting
their high mortality rate, especially in comparison with
those on ART [10]. The increasing mortality share of
those LTFU is a reflection of the growing portion of the
infected population initiating ART, and, at current rates
of loss from care following ART initiation, the number
of those lost from ART care.
Mortality rates among all HIV-infected individuals
have declined from a peak of 72.8 deaths per 1000
person-years in 2004 to 26.3 in 2014 (Fig. 3). These de-
clines are mirrored most strongly in reductions among
those untested and those on ART. Mortality rates among
those unlinked, during pre-ART, or those LTFU have
only declined modestly.
Effects of targeted and combined care improvements
Because Rwanda’s HIV care system is currently function-
ing at a high level in terms of HIV testing, ART coverage,
and retention in care, it’s baseline rate of mortality among
people with HIV is relatively low. Whether this is more
due to efficiency in the program or due to high levels of
investments in HIV control, only combined improvements
to HIV care are expected to lead to large reductions in
mortality rates. Improvements to an isolated part of the
care continuum yield reductions in the contribution to
mortality from that stage of care, with concomitant in-
creases in contributions to mortality from downstream
stages of care. For example, an isolated effort to increase
testing rates could reduce the contribution to mortality
among the untested from 26.8% in 2013 to 3.8% in 2025,
while increasing the contribution to mortality among
those who are unlinked, in pre-ART, LTFU, or on ART by
4.2%–7.7% (Additional file 1: Section S3). A combined
package of improving all aspects of HIV care is expected
to reduce overall mortality rate among HIV-infected indi-
viduals to 19.9 (19.3–20.6) deaths per 1,000 person-years,
Fig. 1 Panel 1a shows overall prevalence calibration (2003–2013) and projection (2014–2025). Dots and uncertainty bars represent prevalence
estimates from UNAIDS (2003 and 2004) and DHS (2005, 2010, and 2013). Red line represents model prevalence, and the shaded area represents
25–75 percentile range from 100 model runs. Panel 1b shows calibration results of prevalence for 5-year age and gender groups. This figure
shows that 7 years after the initial model setup, age- and gender-specific prevalence match estimates from the 2010 population-level DHS survey
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resulting in a declining number of deaths among those
with HIV to 5691 in 2025. In addition, a combined pack-
age of interventions is also expected to result in the great-
est prevalence decline, down to 2.1% (2.0-2.3%) by 2025
(Additional file 1: Section S4).
Discussion
Our analysis provides new insights into mortality among
people with HIV in Rwanda, with potential implications for
other countries in sub-Saharan Africa with similar demog-
raphy and epidemiology. Four principal insights emerge:
first, at the current performance of the HIV healthcare sys-
tem, the combination of growing population size, aging,
and stable HIV prevalence implies that the number of
deaths among HIV-positive individuals are expected to in-
crease; second, while the untested and on-ART populations
currently make the greatest contributions to mortality, the
current levels of testing and ART initiation are expected to
result in a declining share of mortality from those untested
and a growing share from those in ART care; third, among
those not on ART, mortality among those LTFU is expected
to grow the most over the next decade; and, fourth, a com-
bined approach that includes improvements to all aspects
of HIV care may be needed in order to produce meaningful
mortality decline.
We believe our analysis is the first HIV transmission
model calibrated specifically with Rwanda’s epidemiologic
and treatment parameters. HIV care in Rwanda has been
among the best in sub-Saharan Africa in terms of expand-
ing ART coverage through investments in HIV care
infrastructure, adoption of higher CD4 initiation thresh-
olds, and improving HIV testing and linkage rates. At the
same time, like several other sub-Saharan countries with
rapidly growing ART programs, Rwanda had witnessed
flat prevalence rates for much of the last decade and a de-
clining HIV financial budget, such that maximizing care is
a priority. In this complex landscape, our analysis identi-
fies drivers of mortality along the care continuum.
Our modeling approach highlights the important
role played by demographic changes. Specifically for
Rwanda, population growth and aging of the overall
and HIV-infected populations imply that growing
numbers of individuals will die with HIV, often while
remaining in ART and HIV care. On the one hand,
this means that the growing mortality share of those
on ART reflects the desirable survival of this popula-
tion to older ages. On the other hand, it underscores
the future needs to address age-related mortality and
morbidity in this population [32].
The population growth and resulting increasing
deaths in the base case scenario also highlight the
long-term benefits of combined improvements to the
cascade. While immediate ART initiation, as a stand-
alone improvement, reduces mortality overall, those
benefits are modest in comparison with a combined
intervention over a 10-year period. In our model, im-
mediate ART prevents leakage and reduces mortality
among those in pre-ART, and secondarily reduces
mortality through its effects on ongoing transmission
and incidence, but that effect is modest over a 10-
year time horizon. A combined strategy further
Fig. 2 The proportion of deaths among people with HIV by stage of care. Mortality is high among those unlinked to care in the early years of
treatment scale-up, as testing identifies many people with late-stage disease. Over time, the proportion of deaths among those unlinked declines
and those LTFU increases. The portion of deaths among those on ART remains stable, though the mix of AIDS-related and non-AIDS-related
deaths changes over time
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reduces mortality among those untested, unlinked, and
LTFU. However, implementing immediate ART may
be substantially simpler than a combined strategy
(similar to UNAIDS’s 90-90-90 targets), and may sim-
plify HIV care by avoiding pre-ART care.
There are both strengths and limitations to our ana-
lysis. The strengths include our access to Rwandan
specific data and interaction with the Ministry of
Health officials available to provide context. Our
model integrates a large amount of information on
HIV epidemiology and care. Specifically, the mortality
projections rely on data from observational and sur-
veillance cohorts, and any bias in those parameters in-
troduced by selection will propagate in our model. Our
model assumes predominantly heterosexual transmis-
sion. Given stigma associated with men who have sex
with men in Africa and a lack of data on injecting drug
use, it is possible these populations play a larger role
than we accounted for. In addition, while Rwanda’s
population growth has remained stable over the past
decade, our findings of the number of deaths could
change if the demographic projections of population
growth and age structure will change substantially over
the next decade.
As with all model-based analyses, there are trade-offs
regarding the choice of underlying data and modeling
approach. We used a microsimulation modeling tech-
nique to capture the age and gender risk factors that are
highly relevant to the key projections of mortality by dis-
ease stage. The microsimulation modeling approach of-
fers important advantages over deterministic models,
but the extensive data requirements limit the model’s
generalizability. For instance, our model simulates HIV
transmission in Rwanda through heterosexual contact,
with heterogeneity in transmission represented only
through the number of sexual partners. Key populations
such as sex workers or injection drug users play an im-
portant role in the transmission network of HIV, but
Fig. 3 Mortality rate (defined as the number of deaths divided by 1000 person-years lived in the year) among people with HIV. The estimates are
age-adjusted by providing an average of the mortality weighted by the proportion of individuals in each 5-year age group for each health state. Each
panel contains overall HIV mortality rate (dashed black line, right-hand axis) and the mortality rate in different care continuum groups. The first panel
represents the trends assuming base case level of care. Subsequent panels represent the trends with the indicated improvements to HIV care starting
in 2014. A combined intervention with improvements to all aspects of HIV care is projected to lead to the greatest reduction in mortality rates
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the dearth of data on their epidemiology and behavior
limits our ability to incorporate them in the modeling
framework.
Conclusion
In conclusion, estimating the mortality patterns among
those with HIV enables planning of interventions towards
those groups that are expected to shoulder the burden. We
estimate that the greatest increase in mortality among those
not on ART is expected among those LTFU, and the great-
est decline among those untested. However, we also show
that interventions targeting a single part of the HIV care
space will not meaningfully decrease the number of deaths
among those with HIV, and that combined approaches may
be required to continue shrinking the number of deaths
among those with HIV.
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